title: Inhibition of CD147 expression promotes chemosensitivity in HNSCC cells by deactivating MAPK/ERK signaling pathway.
abstract: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world. CD147, a transmembrane glycoprotein, has been reported to be correlated with cancer progression, metastasis, and chemoresistance in various cancers. In this study, we aimed to investigate the mechanism of CD147 in regulating drug resistance in HNSCC cells. qRT-PCR were used to evaluated the expression of CD147 in 57 HNSCC tumorous tissues and 2 cell lines. Increased expression of CD147 was found in most HNSCC samples, and the expression level of CD147 was correlated with multidrug resistance. CD147 RNA silencing decreased the chemoresistance of HNSCC cells by deactivating MAPK/ERK signaling pathway. Further investigation revealed that either rescue expression of CD147 or treatment of MAPK/ERK activator phorbol 12-myristate 13-acetate (PMA) in CD147 knockdown CRC cell line attenuated the decreased chemoresistance in CD147 knockdown cells. Taken together, our results suggest that CD147 promotes chemoresistance by activating MAPK/ERK signaling pathway in HNSCC.
authors.affiliation: Department of oral and maxillofacial surgery, Cangzhou central hospital of Hebei province, Cangzhou 061001, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Ma
authors.affiliation: Department of oral and maxillofacial surgery, Cangzhou central hospital of Hebei province, Cangzhou 061001, China.
authors.forename: Jianqi
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of oral and maxillofacial surgery, Cangzhou central hospital of Hebei province, Cangzhou 061001, China.
authors.forename: Longkun
authors.initials: L
authors.lastname: Fan
authors.affiliation: Department of oral and maxillofacial surgery, Cangzhou central hospital of Hebei province, Cangzhou 061001, China. Electronic address: wallton117@qq.com.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Guo
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D051926:Basigin / Q000235:genetics* / Q000378:metabolism; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D057809:HEK293 Cells; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D051926:Basigin; D020928:Mitogen-Activated Protein Kinases
keywords: CD147; Head and neck squamous cell carcinoma; MAPK/ERK; Multidrug resistance; RNA interference